New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
10:37 EDTATML, ZTS, QEP, TREX, VRSN, REN, BEAV, TAP, ACHN, XXII High option volume stocks
High option volume stocks: ATML ACHN TAP BEAV REN VRSN TREX QEP ZTS XXII
News For ATML;ACHN;TAP;BEAV;REN;VRSN;TREX;QEP;ZTS;XXII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 30, 2014
12:03 EDTACHNAchillion sinks after Johnson & Johnson buys competitor
The shares of Achillion (ACHN), which has developed a treatment for hepatitis C based on a nucleotide and has been viewed as a potential takeover target by analysts previously, are falling after Johnson & Johnson (JNJ) announced this morning that it had agreed to acquire privately held Alios Biopharma. Alios has developed a number of nucleotide-based hepatitis C treatments, as well as an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus. WHAT'S NEW: Johnson & Johnson said that it had agreed to buy Alios for $1.75B. Alios has developed a number of nucleotides that could be used to treat hepatitis C virus, or HCV. Gilead's (GILD) popular HCV treatment Sovaldi is also a nucleotide and Achillion is developing its own HCV nucleotide treatment. According to The Street's Adam Feuerstein, Achillion's nucleotide is similar in structure to that of Alios. Johnson & Johnson had previously been rumored to be interested in buying Achillion, Feuerstein noted. WHAT'S NOTABLE: Johnson & Johnson said it was "excited" that its acquisition of Alios would enable it to "explore treatment options for a number of viral infections, including RSV, the last of the major pediatric diseases with no available preventive therapy." Novavax (NVAX) is also developing an RSV vaccine and Johnson & Johnson could have considered acquiring it before buying Alios, Feuerstein contended. PRICE ACTION: Near noon, Achillion fell 6% to $10.11, Gilead was down 0.6% to $106.84, Novavax dropped 1% to $4.27, and Johnson & Johnson rose 0.4% to just under $107 per share.
10:30 EDTACHNJ&J could have considered Novavax, Achillion instead of Alios, TheStreet says
Subscribe for More Information
September 29, 2014
13:45 EDTXXII22nd Century to participate in a conference call hosted by Wells Fargo
Wells Fargo Tobacco Analyst Herzog hosts CEO Pandolfino on a "Tobacco Talk" conference call to be held on September 30 at 11 am.
September 28, 2014
19:09 EDTTAPMolson Coors shares could rise 30% or more, Barron's says
Molson Coors (TAP) shares could see an increase of 30% or more from three ways, by being a takeover target for SABMiller (SBMRY); if Anheuser-Busch InBev (BUD) acquires SABMiller, then Molson Coors might be able to acquire the remaining interest in MillerCoors for a good price; the company could also rise on its own, driven by cost reductions, Barron's contends in a feature article. Reference Link
September 26, 2014
18:50 EDTACHNRA Capital Management reduces passive stake in Achillion to 11.3% from 18.1%
10:18 EDTACHNOptions with decreasing implied volatility
Subscribe for More Information
September 25, 2014
15:38 EDTACHNAchillion CCO says NUC data won't be abstract at AASLD, Bloomberg reports
Subscribe for More Information
07:25 EDTXXII22nd Century granted meeting with FDA for cigarette development
22nd Century Group announced that the Center for Tobacco Products of the U.S. Food and Drug Administration has granted the company a meeting on November 12 to discuss the further development of the company’s potential modified risk tobacco product, code-named BRAND B, or BB-1, which is a cigarette that is designed to provide an exceptionally low tar-to-nicotine yield ratio. As compared to other commercial low-yield cigarettes, the only differentiating factor of the BB-1 cigarette is that 22nd Century’s high-nicotine tobacco is used, which tobacco is planted, grown, harvested, cured, and processed in exactly the same manner as conventional commercial tobacco. The company intends to demonstrate evidence that 22nd Century’s cigarettes reduce exposure to tobacco toxins and are likely to result in a reduction in morbidity or mortality among individual tobacco users. The purpose of the company’s meeting with CTP will be to seek the Agency’s concurrence that 22nd Century’s proposed BB-1 clinical study is adequate to support the development of BB-1 as a potential modified risk tobacco product. With FDA concurrence, 22nd Century will conduct an exposure study on BB-1 in 1Q15.
September 23, 2014
15:00 EDTACHNAchillion volatility elevated into expected release of viral data
Subscribe for More Information
09:00 EDTZTSBofa/Merill special situations team to hold an analyst/industry conference call
Subscribe for More Information
September 22, 2014
10:36 EDTRENHigh option volume stocks:
Subscribe for More Information
September 19, 2014
07:35 EDTZTSZoetis seen as potential Bayer target after split announcement, Bloomberg says
Subscribe for More Information
06:03 EDTTAPStocks with implied volatility movement; TAP RSH
Stocks with implied volatility movement; Molson Coors (TAP) 31, RadioShack (RSH) 247 according to iVolatility.
September 18, 2014
08:59 EDTXXIIOn The Fly: Pre-market Movers
Subscribe for More Information
08:11 EDTXXII22nd Century announces worldwide license agreement with Anandia
Subscribe for More Information
05:59 EDTTAPMolson Coors implied volatility of 34 at upper end of index mean range
September 17, 2014
11:16 EDTTAPOptions with increasing implied volatility:
Options with increasing implied volatility: WB SDRL TAP AGNC IYR SKX
10:48 EDTTAPHigh option volume stocks
Subscribe for More Information
07:43 EDTZTSBofA/Merrill to hold a conference
Subscribe for More Information
05:56 EDTTAPMolson Coors implied volatility of 33 at upper end of index mean range
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use